p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy

• Published in: Cancers Vol. 16; no. 2; p. 256
• Main Authors: Morales-Martínez, Mario, Vega, Mario I
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Apoptosis; Autophagy; Binding sites; Cancer; cancer progression; Cancer therapies; Carfilzomib; Cell adhesion & migration; Cell growth; Chemical inhibitors; Chemoresistance; Chemotherapy; clinical implication; Cytokines; Development and progression; Disease resistance; gene expression; Health aspects; Immunotherapy; Isoforms; Kinases; MAP kinase; Metabolism; Mitogens; Multiple myeloma; p38; Phosphorylation; Protein kinases; Proteins; Radiation therapy; Signal transduction; Therapeutic applications; Transcription factors; transcriptional factor; Tumors; multiple myeloma; cancer progression; clinical implication; p38; transcriptional factor; gene expression
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16020256

Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.